TrialSignal transduction and targeted therapy2022

Clinical utility of PDX cohorts to reveal biomarkers of intrinsic resistance and clonal architecture changes underlying acquired resistance to cetuximab in HNSCC.

Yanli Yao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.